Scarica l'app Stockscreener
2.18
5.31%
0.11
Dopo l'orario di chiusura:
2.22
0.04
+1.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.07
Aprire:
$2.08
Volume 24 ore:
3.19M
Relative Volume:
1.11
Capitalizzazione di mercato:
$739.96M
Reddito:
$775.09M
Utile/perdita netta:
$-58.68M
Rapporto P/E:
-16.44
EPS:
-0.1326
Flusso di cassa netto:
$64.06M
1 W Prestazione:
-11.02%
1M Prestazione:
-1.36%
6M Prestazione:
-49.07%
1 anno Prestazione:
-53.32%
Intervallo 1D:
$2.08
$2.24
Intervallo di 1 settimana:
$1.77
$2.24
Portata 52W:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.18 | 702.63M | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
188.48 | 30.56B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
51.29 | 9.19B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.96 | 7.33B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
81.15 | 6.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.93 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
Is GoodRx (GDRX) Using Employer Direct to Redefine Its Role in Workplace Drug Benefits? - Sahm
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
GoodRx Announces Resignation of Board Member Dipanjan Deb - TipRanks
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho - MarketBeat
Hims & Hers Expands Digital Health and Global Platform Strategy - TradingView
GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says - marketscreener.com
UBS Lowers Price Target on GoodRx Holdings to $2 From $4, Maintains Neutral Rating - marketscreener.com
Raymond James cuts GoodRx stock price target on pharma headwinds - Investing.com
JPMorgan Chase & Co. Reaffirms Neutral Rating for GoodRx (NASDAQ:GDRX) - MarketBeat
A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts - Benzinga
GoodRx Holdings (GDRX) Downgraded by JP Morgan to Neutral | GDRX Stock News - GuruFocus
JPMorgan Downgrades GoodRx to Neutral From Overweight - marketscreener.com
Morgan Stanley Cuts Price Target on GoodRx Holdings to $3 From $4, Keeps Equalweight Rating - marketscreener.com
GDRX: GoodRx drives ~$17B in annual consumer savings and achieves profitable growth with expanding partnerships - TradingView
Raymond James cuts GoodRx stock price target on pharma headwinds By Investing.com - Investing.com South Africa
GoodRx Q4 2025 Earnings: Revenue Down, Future Guidance Below EstimatesNews and Statistics - IndexBox
GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Leerink Maintains Outperform on GoodRx (GDRX) Feb 26, 2026 PT $3 - Meyka
JPMorgan Downgrades GoodRx Holdings Inc. (GDRX) to Neutral - StreetInsider
GoodRx Holdings Inc. (GDRX) PT Lowered to $1.90 at BofA Securities - StreetInsider
GoodRx Holdings Inc (GDRX) Q4 2025 Earnings Call Highlights: Pha - GuruFocus
GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions - MSN
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Leerink cuts GoodRx stock price target to $3 on weak guidance - Investing.com Australia
GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners - StreetInsider
GoodRx (NASDAQ:GDRX) Sets New 52-Week LowHere's What Happened - MarketBeat
GDRX: Pharma Direct revenue surged 41% in 2025, driving growth amid evolving healthcare trends - TradingView
Earnings call transcript: GoodRx Q4 2025 revenue meets expectations amid strategic shifts - Investing.com
GDRX: Pharma Direct and subscriptions drive growth amid near-term revenue pressure and strategic shifts - TradingView
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings - Yahoo Finance
Q4 2025 GoodRx Holdings Inc Earnings Call Transcript - GuruFocus
GoodRx Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GoodRx Holdings Inc. (GDRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
GoodRx Reports Fourth Quarter and Full Year 2025 Results - PharmiWeb.com
GoodRx (GDRX) Sees High Call Activity Ahead of Earnings - GuruFocus
GoodRx Holdings options imply 10.2% move in share price post-earnings - TipRanks
GoodRx’s (NASDAQ:GDRX) Q4 CY2025 Sales Top Estimates But Stock Drops 11.8% - Yahoo Finance
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):